This week, a retired competitive agility dog dons prescription eyewear, botulism toxin becomes a first-line treatment for blepharospasm and GenSight’s experimental gene therapy for Leber’s neuropathy shows sustained benefits at 2 years. Source: AAO
Investigators report the use of a topical tacrolimus monotherapy for vernal keratoconjunctivitis (VKC). Source: AAO
This paper characterizes the clinical and neuroimaging findings in severe cases of myelin oligodendrocyte glycoprotein (MOG) antibody–positive bilateral recurrent optic neuritis (ON). Source: AAO
Aflibercept is now an approved treatment for all stages of diabetic retinopathy (DR), making it the only anti-VEGF agent with two dosing options for DR. Source: AAO
In this study, researchers assessed the cycloplegic and mydriatic effects of omitting tropicamide from a common pediatric eye drop combination. Source: AAO
Investigators retrospectively compared visual and anatomical outcomes among chronic central serous chorioretinopathy (CSR) patients treated with oral spironolactone or half-dose photodynamic therapy (PDT). Source: AAO
This is the first report of cytomegalovirus (CMV) corneal endotheliitis after Descemet membrane endothelial keratoplasty (DMEK). Source: AAO
The prescription dry eye treatment lifitegrast (Xiidra) will change hands from Takeda to Novartis later this year, at an estimated cost of $5.3 billion. Source: AAO
Optina Diagnostics has received the breakthrough device designation for their retinal scanner designed to aid in the early detection of Alzheimer disease. Source: AAO
This week, a collision-detecting suitcase helps blind people navigate airports, an enzyme-based drop soothes dry eyes and an Ophtec capsular tension ring injector gets a design overhaul. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »
